3 documents found, page 1 of 1
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an i...
Gurnari, Carmelo; Robin, Marie; Adès, Lionel; Aljurf, Mahmoud; Almeida, António M.; Duarte, Fernando Barroso; Bernard, Elsa; Cutler, CoreyFor patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment clinical trials have indicated that in eligible patients, allo-HCT is associated with superior clinical outcomes co...
Fitness assessment in acute myeloid leukemia: recommendations from an expert pa...
Venditti, Adriano; Palmieri, Raffaele; Maurillo, Luca; Röllig, Christoph; Wierzbowska, Agnieszka; de Leeuw, David; Efficace, Fabio; Curti, AntonioFitness assessment in patients with acute myeloid leukemia (AML) is critical to deliver the right therapy to the right patient. Although several scoring systems are available to aid in determining fitness, the absence of validation studies has resulted in the lack of universally accepted assessment procedures. This limitation, combined with the increasing availability of novel agents expanding the spectrum of l...
Immune-monitoring of myelodysplastic neoplasms: recommendations from the i4MDS ...
i4MDS consortium; Tentori, Cristina A.; Zhao, Lin P.; Tinterri, Benedetta; Strange, Kathryn E.; Zoldan, Katharina; Dimopoulos, KonstantinosAdvancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly in recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While molecular inclusions into prognostic models have substantively advanced risk stratification, recent revelations have emphasized the pivotal role of immune dysregulation within the bone marrow milieu during M...